John M Curto

This inventor holds 15 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 5 EPO patents. Top assignee: Pfizer Corporation. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John M Curto. Retrieved from https://idiyas.com/inventor/john-m-curto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 14.9

ph-index = 6

Forward Citations = 82(Granted Patents)

Company Filing History:

15 out of 4,486

Pfizer Corporation

patents

Years Active: 2019-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637461 - Compounds for the activation of AMPK (2026-05-26),

2. 12611401 - Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases (2026-04-28),

3. 12378230 - GLP-1 receptor agonists and uses thereof (2025-08-05),

4. 12331041 - GLP-1 receptor agonists and uses thereof (2025-06-17),

5. 12319669 - GLP-1 receptor agonists and uses thereof (2025-06-03),

6. 11858916 - GLP-1 receptor agonists and uses thereof (2024-01-02),

7. 11802121 - GLP-1 receptor agonists and uses thereof (2023-10-31),

8. 11512070 - GLP-1 receptor agonists and uses thereof (2022-11-29),

9. 11203594 - Anti-proliferative agents for treating PAH (2021-12-21),

10. 10934279 - GLP-1 receptor agonists and uses thereof (2021-03-02),

11. 10851081 - GLP-1 receptor agonists and uses thereof (2020-12-01),

12. 10683281 - GLP-1 receptor agonists and uses thereof (2020-06-16),

13. 10676465 - GLP-1 receptor agonists and uses thereof (2020-06-09),

14. 10669259 - GLP-1 receptor agonists and uses thereof (2020-06-02),

15. 10208019 - GLP-1 receptor agonists and uses thereof (2019-02-19),

Title: The Innovative Contributions of John M. Curto in the Field of Pharmaceuticals

Introduction: John M. Curto is a distinguished inventor based in Mystic, CT, known for his significant contributions to pharmaceutical innovations. With an impressive portfolio of 13 patents, Curto focuses primarily on the development of GLP-1 receptor agonists, which play a critical role in treating various medical conditions.

Latest Patents: Among his latest inventions, Curto has developed patents related to GLP-1 receptor agonists. These patents include a detailed description of 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists. The patents also outline processes for synthesizing these compounds and methods for administering them to mammals in need of such treatments. This work reflects Curto's commitment to advancing medical science through innovative solutions.

Career Highlights: John M. Curto currently works at Pfizer Corporation, where he continues to drive innovation in drug development. His extensive experience in pharmaceutical research has established him as a leading figure in the industry, contributing to a variety of projects that aim to enhance patient care and outcomes.

Collaborations: Throughout his career, Curto has collaborated with esteemed colleagues such as Scott William Bagley and Mark Edward Flanagan. These partnerships have fostered a rich environment for innovation, enabling the team to push the boundaries of pharmaceutical research and achieve major breakthroughs.

Conclusion: John M. Curto's dedication to innovation in the pharmaceutical field is evident through his numerous patents and collaborations. As a key contributor at Pfizer Corporation, his work on GLP-1 receptor agonists exemplifies the impact that targeted research and development can have on improving health outcomes. Curto’s contributions continue to inspire future inventors and researchers in the quest for new therapeutic solutions.

Profile summary based on public USPTO records.